Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2025

This “Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2025” report provides comprehensive insights about 9+ companies and 11+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Advanced Non-Squamous & Squamous NSCLC: Understanding

Advanced Non-Squamous & Squamous NSCLC: Overview

Lung cancer, particularly non-small-cell lung cancer (NSCLC), is a significant global health concern, with adenocarcinoma (LUAD) and squamous cell carcinoma (LSCC) being the most common subtypes. For advanced NSCLC patients, personalized treatment plans involving chemotherapy, immune checkpoint inhibitors, and targeted therapies are crucial. Targeted therapies, which interfere with specific tumor molecules, are recommended for patients with actionable mutations identified through tumor genetic profiling, often using next-generation sequencing (NGS). FDA-approved targeted agents target genetic driver alterations like EGFR mutations, ALK/ROS1/RET rearrangements, NTRK fusions, MET exon 14 skipping mutation, KRAS G12C mutation, BRAF V600E mutation, and ERBB2 (HER2) mutation. Ongoing research aims to develop new agents for these targets, overcome treatment resistance, and explore novel driver mutations for therapeutic targeting, including traditionally not druggable mutations.

The etiology of non-small-cell lung cancer (NSCLC) involves avoidable and unavoidable risk factors. Inhaled tobacco use is the most prominent avoidable risk factor, while other causes include alcohol use, exposure to secondhand smoke, asbestos, radon, arsenic, chromium, nickel, ionizing radiation, and polycyclic aromatic hydrocarbons. Additionally, radiation therapy for other cancers like breast cancer can lead to primary lung cancer. Patients with pulmonary fibrosis face a significantly higher risk of developing lung cancer, independent of tobacco use. Moreover, individuals with HIV have an increased incidence of lung cancer, irrespective of smoking habits or antiretroviral therapy, highlighting the multifactorial nature of NSCLC development.

Advanced non-squamous and squamous non-small cell lung cancer (NSCLC) present with distinct signs and symptoms. In advanced non-squamous NSCLC, common indicators include more breathing difficulties, bone pain, abdominal or back pain, headaches, weakness, seizures, speech difficulties, and hormonal imbalances due to tumor-secreted hormones. On the other hand, squamous NSCLC patients may experience symptoms like chronic cough, sputum with blood, hoarseness, and fever. These symptoms often correlate with the stage and pathological diagnosis of NSCLC, with more advanced stages showing a higher likelihood of symptom development, emphasizing the importance of early detection and tailored treatment approaches.

Treatment for advanced non-squamous and squamous non-small cell lung cancer (NSCLC) involves a multidisciplinary approach. For non-squamous NSCLC, treatment options include targeted therapies such as EGFR tyrosine kinase inhibitors like osimertinib, immunotherapy with atezolizumab, and chemotherapy with doublets containing platinum compounds. For squamous NSCLC, treatment often involves platinum-based chemotherapy regimens, such as docetaxel and pemetrexed, and targeted therapies like erlotinib. Additionally, immunotherapy with pembrolizumab and nivolumab have shown efficacy in both non-squamous and squamous NSCLC.

'Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Non-Squamous & Squamous NSCLC pipeline landscape is provided which includes the disease overview and Advanced Non-Squamous & Squamous NSCLC treatment guidelines. The assessment part of the report embraces, in depth Advanced Non-Squamous & Squamous NSCLC commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Non-Squamous & Squamous NSCLC collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Non-Squamous & Squamous NSCLC R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Non-Squamous & Squamous NSCLC.

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs Chapters

This segment of the Advanced Non-Squamous & Squamous NSCLC report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs

Erfonrilimab: Jiangsu Alphamab Biopharmaceuticals

KN-046 (Erfonrilimab) is a bispecific antibody targeting both programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The drug is currently being evaluated under the Phase III clinical trial for the treatment of Advanced Squamous Non-small Cell Lung Cancer.

Pyrotinib: Jiangsu HengRui Medicine

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients suffering from advanced non-squamous NSCLC.

Advanced Non-Squamous & Squamous NSCLC: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Non-Squamous & Squamous NSCLC drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Non-Squamous & Squamous NSCLC

There are approx. 9+ key companies which are developing the therapies for Advanced Non-Squamous & Squamous NSCLC. The companies which have their Advanced Non-Squamous & Squamous NSCLC drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu Alphamab Biopharmaceuticals.

Phases

The report covers around 11+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Advanced Non-Squamous & Squamous NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Non-Squamous & Squamous NSCLC: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Non-Squamous & Squamous NSCLC therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Non-Squamous & Squamous NSCLC drugs.

Advanced Non-Squamous & Squamous NSCLC Report Insights

• Advanced Non-Squamous & Squamous NSCLC Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Non-Squamous & Squamous NSCLC Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Non-Squamous & Squamous NSCLC drugs?
• How many Advanced Non-Squamous & Squamous NSCLC drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Non-Squamous & Squamous NSCLC?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Non-Squamous & Squamous NSCLC therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Non-Squamous & Squamous NSCLC and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu Alphamab Biopharmaceuticals
• Jiangsu HengRui Medicine
• Novartis Pharmaceuticals
• Genentech

Key Products

• Erfonrilimab
• Pyrotinib
• Canakinumab
• Tiragolumab

This product will be delivered within 2 business days.